Core Insights - The global interest in China's biopharma sector is driven by the lower costs of early clinical programs compared to the US and Europe, with expectations for increased dealmaking between China and the West as 2026 approaches [1][2] Group 1: Deal Trends and Values - There has been a significant rise in high-value deals between the West and China, with 20 transactions exceeding $500 million in 2023 alone [2] - Major deals in 2025 include Novartis's $5.36 billion agreement with Argo Biopharmaceutical, AstraZeneca's $5.3 billion deal with CSPC Pharmaceutical, and Zenas Biopharma's $2 billion agreement with InnoCare Pharma [2] - Chinese innovator drug licensing deals accounted for 28% of the innovator deals signed by large pharma in 2024, totaling $41.5 billion in value [3] Group 2: R&D and Therapeutic Focus - Western companies are increasingly seeking partnerships with Chinese biotech firms to enhance their pipelines with cost-effective therapies, particularly in oncology, immunology, and cardiometabolic health [4] - The rapid growth of China's clinical trial ecosystem has positioned the country as a leader in global study initiations in 2024 [5] - China is shifting from a reputation for generic drug manufacturing to developing innovative therapies, capturing global pharmaceutical attention [6] Group 3: Oncology and Innovative Therapies - Oncology remains a focal point for licensing agreements, with significant deals from companies like AbbVie, Pfizer, and GSK [9] - Antibody-drug conjugates (ADCs) developed in China are particularly appealing to Western dealmakers due to their innovative potential [10] - Next-generation biologics, including ADCs, bispecifics, and cell and gene therapies, are driving interest from investors and large pharmaceutical companies [11] Group 4: Future Outlook and Strategic Shifts - Immunology is expected to remain a key area of focus in 2026, alongside a rise in cardiometabolic deals targeting the obesity market [13] - The BIOSECURE Act could impact interactions between Western and Chinese companies, but industry leaders express confidence in the resilience of innovation-driven strategies [14][16] - Some Chinese companies are exploring self-commercialization strategies, although most will likely continue to rely on licensing deals in the near term due to a lack of global market experience [18][19]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.91% on December 16, with a trading volume of 1.078 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 15, 2024, the fund's total shares reached 10.425 billion, with a total size of 8.174 billion yuan, reflecting a significant increase in shares and size compared to the previous year [1] Fund Performance - The fund manager, Ma Jun, has achieved a return of 64.28% since taking over management on January 3, 2024 [2] - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] Holdings Overview - Major holdings in the fund include: - BeiGene (10.62% holding, market value 817 million yuan) - CanSino Biologics (10.55% holding, market value 812 million yuan) - Innovent Biologics (10.21% holding, market value 786 million yuan) - China National Pharmaceutical Group (9.62% holding, market value 741 million yuan) - CSPC Pharmaceutical Group (7.56% holding, market value 583 million yuan) [2]

智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临 床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为 未来License-out项目的重点方向。我国创新药企业已从高投入低产出的研发探索期过渡到了管线密集收 获期，与此同时商保的发展有望让原先的创新药"单一"支付向多元支付转型。此外，医疗器械2025年招 采端持续复苏，关注设备更新政策与资金落地持续驱动需求释放。 东方财富证券主要观点如下： 标的方面 创新药板块建议关注百济神州(06160)、恒瑞医药(01276)、中国生物制药(01177)、三生制药(01530)/三生 国健(688336.SH)、石药集团(01093)等。医疗器械板块：1）内需修复：建议关注迈瑞医疗(300760.SZ)、 联影医疗(688271.SH)、开立医疗(300633.SZ)、澳华内镜(688212.SH)等；2）出海兑现：建议关注海泰新 光(688677.SH)、新产业(300832.SZ)等；3）脑机接口：建议关注诚益通(300430.SZ)、伟思医疗 (688580.SH)等。 ...

Market Overview - Major Asia-Pacific stock indices experienced a decline, with the Nikkei 225 and the Korea Composite Index both dropping over 1% [1] - A-shares and Hong Kong's Hang Seng Index also fell, with the FTSE China A50 Index futures down more than 1% [1] - Precious metal futures mostly decreased, and cryptocurrencies continued to decline significantly [1] A-Shares Performance - A-shares showed volatility in early trading, with the Shanghai Composite Index and Shenzhen Component Index both down over 1%, while the ChiNext Index fell over 2% [2] - The Northbound Trading of the Shanghai and Shenzhen Stock Connect saw the Northbound 50 Index rise over 1% [2] - A total of 4,464 stocks in the market declined [2] Sector Performance - The photovoltaic and energy storage sectors continued to adjust, with companies like Dongfang Risen falling over 10% and Zhongli Group nearing a trading halt [4] - Precious metal stocks also saw declines, with Western Gold and Xiaocheng Technology dropping over 6% [4] - Retail concepts remained active, with Baida Group achieving four consecutive trading limits, while smart driving concepts strengthened, with companies like Beiqi Blue Valley hitting trading limits [5] Cryptocurrency Market - Cryptocurrencies faced significant declines, with Bitcoin dropping below $86,000, leading to over 180,000 liquidations in the past 24 hours [6]

Company Overview - The company, Shiyao Innovation, submitted its prospectus to the Hong Kong Stock Exchange on December 10, 2025, aiming for a mainboard listing, with CITIC Securities as the sole sponsor [1] - Shiyao Innovation was spun off from Shiyao Group and was listed on the A-share market in March 2019, with a market capitalization of 47.5 billion RMB as of December 11 [1] - The company focuses on biopharmaceuticals, functional raw materials, and health foods, reporting revenues of 1.98 billion RMB in 2024 and a net loss of 304 million RMB [1] Financial Performance - For the first seven months of 2025, the company reported revenues of 1.24 billion RMB, a year-on-year increase of 8.74%, with a net loss of 226 million RMB [8] - The gross profit margin for the first seven months of 2025 was 38.27%, while the R&D expense ratio was approximately 42.67% [8] - The company has seen a significant increase in net loss year-on-year, with a 483.69% increase in net loss for the first seven months of 2025 compared to the previous year [8] Product and Market Focus - The company has expanded its main business into the biopharmaceutical sector by acquiring control of Giant Rock Biotech in 2024, marking a strategic shift in its development [1] - Shiyao Innovation is the largest producer of synthetic caffeine globally from 2020 to 2024, supplying major companies like Coca-Cola, PepsiCo, and Red Bull [1] - The company is strategically focusing on antibody drugs, ADCs, and mRNA vaccines, with a strong pipeline of 15 drugs in clinical or late-stage development, including 9 ADCs and 1 mRNA vaccine [3][5] Industry Insights - The global antibody drug market is projected to grow from $163.8 billion in 2019 to $254.3 billion in 2024, with a compound annual growth rate (CAGR) of 9.2% [10] - The synthetic caffeine market is expected to grow from $391.4 million in 2019 to $578.5 million in 2024, with a CAGR of 8.1% [19] - The company holds a 51.5% market share in China's synthetic caffeine market as of 2024 [20]

Group 1 - The innovative drug concept stocks have declined again, with notable drops in share prices for several companies [1] - Innovent Biologics (09969.HK) fell by 5.09%, trading at HKD 12.86 [1] - CSPC Pharmaceutical Group (01093.HK) decreased by 3.99%, with shares priced at HKD 7.21 [1] - Sinopharm Group (01801.HK) saw a decline of 3.36%, with its stock at HKD 79 [1]

Group 1 - The core viewpoint of the article highlights a decline in innovative drug concept stocks, with notable drops in companies such as Innovent Biologics (down 5.09% to HKD 12.86), CSPC Pharmaceutical Group (down 3.99% to HKD 7.21), and Sinopharm Group (down 3.36% to HKD 79) [1] - China Post Securities notes that despite a temporary vacuum in domestic BD (business development) transactions since the second half of the year, there have been multiple transactions involving overseas MNCs as partners since Q4, indicating ongoing activity in the sector [1] - The firm believes that the purchasing behavior of overseas MNCs serves as a recognition of the innovative research and development capabilities of domestic innovative drug companies, reflecting strong competitive advantages in the global market [1] Group 2 - A significant event occurred with the A-share innovative drug stock Yipinhong, which unexpectedly hit the daily limit down yesterday and fell over 13% this morning, following a buyout offer for its stake in the US company Arthrosi, with a total transaction amount potentially reaching USD 1.5 billion [1] - Analysts suggest that the transaction involving Yipinhong may alter market expectations, as the previous market sentiment anticipated a BD based on the current acquisition price, but the situation has shifted to a direct sale, leading to a decline in stock price [1] - The stock price of Yipinhong had previously surged, reflecting expectations of BD, but the weakening of these expectations has resulted in the recent price drop [1]

值得关注的是，A股创新药大牛股一品红（300723）昨日意外跌停，今早再跌超13%。该公司参股的美 国Arthrosi公司收到收购要约，交易总金额最高可达15亿美元。有分析称，一品红的交易可能改变了一 些市场预期。此前市场预期的这个标的是按现在的收购价进行BD，但现在是直接卖出。而此前，股价 上涨太多，并且反应的是BD，现在预期走弱，故而股价跌停。 创新药概念股再度走低，截至发稿，诺诚健华(09969)跌5.09%，报12.86港元；石药集团(01093)跌 3.99%，报7.21港元；信达生物(01801)跌3.36%，报79港元。 中邮证券指出，下半年以来，国内的BD出海交易虽有短暂真空，但仍在持续，Q4以来亦诞生了多个 MNC为合作方的交易。该行认为，海外MNC的购买行为系对国内创新药公司创新研发的实力的背书认 可。进一步看，该行认为系中国创新药产业链能力、管线数量和质量、研发效率在全球的强大竞争优势 催生出的结果，坚定看好长期的产业趋势。 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced net redemptions of 1.3343 million yuan on December 15, ranking 15th out of 200 in cross-border ETF net outflows, with a latest scale of 5.062 billion yuan, down from 5.304 billion yuan the previous day [1][2] Group 1: Fund Performance - As of December 15, the latest share count for the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) is 3.846 billion shares, with a total scale of 5.062 billion yuan [2] - Over the past 20 trading days, the cumulative trading amount for the ETF is 10.835 billion yuan, with an average daily trading amount of 542 million yuan [2] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 31.62% and 50.01% respectively since their management began [2] Group 2: Holdings and Composition - The top holdings of the fund include companies such as BeiGene (百济神州) at 10.84%, CanSino Biologics (康方生物) at 10.77%, and Innovent Biologics (信达生物) at 10.43%, among others [2] - The fund's management fee is 0.40% per annum, and the custody fee is 0.07% per annum [1][2] Group 3: Comparative Analysis - The fund ranks 34th in net outflows over the past 5 days and 11th over the past 10 days, while it ranked 51st in net inflows over the past 20 days with a net subscription of 102 million yuan [1][2] - Other ETFs tracking the same index include Huatai-PineBridge (汇添富), with a scale of 22.394 billion yuan, and Yinhua (银华), with a scale of 8.174 billion yuan, showing varying levels of net subscriptions and trading volumes [2]

Core Viewpoint - The recent data indicates a significant adjustment in the sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping 3.32% to a five-month low, while over 75 million yuan was invested in the fund, marking a continuous inflow of over 200 million yuan in the past six days [1][9]. Fund Performance - The latest share count for the Hong Kong Stock Connect Innovative Drug ETF (520880) reached 4.148 billion shares, a record high since its launch, with the fund size at 2.165 billion yuan, also at a historical peak [4][11]. Market Dynamics - The fund's recent inflow is attributed to its value proposition, as the underlying index has seen a 21.56% pullback since early September, suggesting a favorable time for medium to long-term investment in core innovative drug assets [3][13]. - The National Healthcare Security Administration emphasized the importance of promoting innovative drug insurance coverage, encouraging commercial health insurance to include more reasonable medical expenses outside the basic insurance catalog [3][13]. Sector Outlook - Despite recent fluctuations in sentiment, the outlook for the innovative drug industry remains positive, with expectations for increased global competitiveness, successful international expansion, and commercial profitability by Q1 2026 [3][13]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted for its unique advantages, including a pure focus on innovative drug companies, a significant weight of over 72% in leading firms, and controlled risks through the reduction of illiquid stocks [5][6][13]. Index Composition - The top ten holdings in the ETF account for 72.57% of the total weight, showcasing the dominance of leading companies in the innovative drug sector [7][14].